blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2595964

EP2595964 - Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them [Right-click to bookmark this link]
Former [2013/22]PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
[2014/50]
StatusNo opposition filed within time limit
Status updated on  04.03.2016
Database last updated on 12.11.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
Domainex Limited
162 Cambridge Science Park
Milton Road
Cambridge CB4 0GH / GB
[2013/22]
Inventor(s)01 / PERRIOR, Trevor, Robert
Domainex Limited
162 Cambridge Science Park
Milton Road
Cambridge CB4 0GH / GB
02 / NEWTON, Gary, Karl
Domainex Limited
162 Cambridge Science Park
Milton Road
Cambridge CB4 0GH / GB
03 / STEWART, Mark, Richard
Domainex Limited
162 Cambridge Science Park
Milton Road
Cambridge CB4 0GH / GB
04 / AQIL, Rehan
Domainex Limited
162 Cambridge Science Park
Milton Road
Cambridge CB4 0GH / GB
 [2013/22]
Representative(s)Scott, Susan Margaret
Abel & Imray
20 Red Lion Street
London WC1R 4PQ / GB
[2015/18]
Former [2013/22]Scott, Susan Margaret
Abel & Imray 20 Red Lion Street
London WC1R 4PQ / GB
Application number, filing date11738026.118.07.2011
WO2011GB01075
Priority number, dateGB2010001210519.07.2010         Original published format: GB 201012105
[2013/22]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012010826
Date:26.01.2012
Language:EN
[2012/04]
Type: A1 Application with search report 
No.:EP2595964
Date:29.05.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 26.01.2012 takes the place of the publication of the European patent application.
[2013/22]
Type: B1 Patent specification 
No.:EP2595964
Date:29.04.2015
Language:EN
[2015/18]
Search report(s)International search report - published on:EP26.01.2012
ClassificationIPC:C07D239/42, C07D401/12, C07D401/14, C07D403/12, A61K31/506, A61P29/00, A61P35/00
[2013/22]
CPC:
C07D403/10 (EP,US); A61P1/00 (EP); A61P11/00 (EP);
A61P11/06 (EP); A61P13/12 (EP); A61P17/00 (EP);
A61P19/02 (EP); A61P19/10 (EP); A61P25/28 (EP);
A61P27/02 (EP); A61P29/00 (EP); A61P3/04 (EP);
A61P3/10 (EP); A61P31/00 (EP); A61P31/04 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P37/06 (EP);
A61P43/00 (EP); A61P9/10 (EP); C07D239/42 (EP,US);
C07D401/12 (EP,US); C07D401/14 (EP,US); C07D403/12 (EP,US);
C07D403/14 (EP,US); C07D413/14 (EP,US); C07D417/14 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/22]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:Pyrimidinverbindungen als Hemmer der IKK epsilon und/oder TBK-1 Proteinkinasen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen[2014/50]
English:Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them[2014/50]
French:Composés pyrimidines comme inhibiteurs de protéine kinases IKK epsilon et/ou TBK-1, procédé pour leur préparation et compositions pharmaceutiques les contenant[2014/50]
Former [2013/22]PYRIMIDINVERBINDUNGEN ALS HEMMER DER PROTEINKINASEN IKK EPSOLON UND/ODER TBK-1, VERFAHREN ZU IHRER HERSTELLUNG UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN DAMIT
Former [2013/22]PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Former [2013/22]PYRIMIDINES AU TITRE D'INHIBITEURS DE PROTÉINES KINASES IKK EPSILON ET/OU TBK-1, LEURS PROCÉDÉS DE SYNTHÈSE ET LES COMPOSITIONS PHARMACEUTIQUES LES INCLUANT
Entry into regional phase14.02.2013National basic fee paid 
14.02.2013Designation fee(s) paid 
14.02.2013Examination fee paid 
Examination procedure14.02.2013Examination requested  [2013/22]
09.09.2013Amendment by applicant (claims and/or description)
13.11.2014Communication of intention to grant the patent
18.03.2015Fee for grant paid
18.03.2015Fee for publishing/printing paid
18.03.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  13.11.2014
Opposition(s)01.02.2016No opposition filed within time limit [2016/14]
Fees paidRenewal fee
10.07.2013Renewal fee patent year 03
14.07.2014Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU18.07.2011
AL29.04.2015
AT29.04.2015
BE29.04.2015
BG29.04.2015
CY29.04.2015
CZ29.04.2015
DK29.04.2015
EE29.04.2015
ES29.04.2015
FI29.04.2015
HR29.04.2015
IT29.04.2015
LT29.04.2015
LV29.04.2015
MC29.04.2015
MK29.04.2015
MT29.04.2015
NL29.04.2015
PL29.04.2015
RO29.04.2015
RS29.04.2015
SE29.04.2015
SI29.04.2015
SK29.04.2015
SM29.04.2015
TR29.04.2015
IE18.07.2015
LU18.07.2015
NO29.07.2015
GR30.07.2015
IS29.08.2015
PT31.08.2015
[2018/46]
Former [2018/31]HU18.07.2011
AT29.04.2015
BE29.04.2015
BG29.04.2015
CY29.04.2015
CZ29.04.2015
DK29.04.2015
EE29.04.2015
ES29.04.2015
FI29.04.2015
HR29.04.2015
IT29.04.2015
LT29.04.2015
LV29.04.2015
MC29.04.2015
MK29.04.2015
MT29.04.2015
NL29.04.2015
PL29.04.2015
RO29.04.2015
RS29.04.2015
SE29.04.2015
SI29.04.2015
SK29.04.2015
SM29.04.2015
TR29.04.2015
IE18.07.2015
LU18.07.2015
NO29.07.2015
GR30.07.2015
IS29.08.2015
PT31.08.2015
Former [2017/39]HU18.07.2011
AT29.04.2015
BE29.04.2015
BG29.04.2015
CY29.04.2015
CZ29.04.2015
DK29.04.2015
EE29.04.2015
ES29.04.2015
FI29.04.2015
HR29.04.2015
IT29.04.2015
LT29.04.2015
LV29.04.2015
MC29.04.2015
MT29.04.2015
NL29.04.2015
PL29.04.2015
RO29.04.2015
RS29.04.2015
SE29.04.2015
SI29.04.2015
SK29.04.2015
SM29.04.2015
TR29.04.2015
IE18.07.2015
LU18.07.2015
NO29.07.2015
GR30.07.2015
IS29.08.2015
PT31.08.2015
Former [2017/22]AT29.04.2015
BE29.04.2015
CZ29.04.2015
DK29.04.2015
EE29.04.2015
ES29.04.2015
FI29.04.2015
HR29.04.2015
IT29.04.2015
LT29.04.2015
LV29.04.2015
MC29.04.2015
MT29.04.2015
NL29.04.2015
PL29.04.2015
RO29.04.2015
RS29.04.2015
SI29.04.2015
SK29.04.2015
IE18.07.2015
LU18.07.2015
NO29.07.2015
GR30.07.2015
IS29.08.2015
PT31.08.2015
Former [2016/37]AT29.04.2015
BE29.04.2015
CZ29.04.2015
DK29.04.2015
EE29.04.2015
ES29.04.2015
FI29.04.2015
HR29.04.2015
IT29.04.2015
LT29.04.2015
LV29.04.2015
MC29.04.2015
NL29.04.2015
PL29.04.2015
RO29.04.2015
RS29.04.2015
SI29.04.2015
SK29.04.2015
IE18.07.2015
LU18.07.2015
NO29.07.2015
GR30.07.2015
IS29.08.2015
PT31.08.2015
Former [2016/33]AT29.04.2015
CZ29.04.2015
DK29.04.2015
EE29.04.2015
ES29.04.2015
FI29.04.2015
HR29.04.2015
IT29.04.2015
LT29.04.2015
LV29.04.2015
MC29.04.2015
NL29.04.2015
PL29.04.2015
RO29.04.2015
RS29.04.2015
SI29.04.2015
SK29.04.2015
IE18.07.2015
LU18.07.2015
NO29.07.2015
GR30.07.2015
IS29.08.2015
PT31.08.2015
Former [2016/24]AT29.04.2015
CZ29.04.2015
DK29.04.2015
EE29.04.2015
ES29.04.2015
FI29.04.2015
HR29.04.2015
IT29.04.2015
LT29.04.2015
LV29.04.2015
MC29.04.2015
NL29.04.2015
PL29.04.2015
RO29.04.2015
RS29.04.2015
SI29.04.2015
SK29.04.2015
LU18.07.2015
NO29.07.2015
GR30.07.2015
IS29.08.2015
PT31.08.2015
Former [2016/21]AT29.04.2015
CZ29.04.2015
DK29.04.2015
EE29.04.2015
ES29.04.2015
FI29.04.2015
HR29.04.2015
IT29.04.2015
LT29.04.2015
LV29.04.2015
MC29.04.2015
NL29.04.2015
PL29.04.2015
RO29.04.2015
RS29.04.2015
SK29.04.2015
LU18.07.2015
NO29.07.2015
GR30.07.2015
IS29.08.2015
PT31.08.2015
Former [2016/15]AT29.04.2015
CZ29.04.2015
DK29.04.2015
EE29.04.2015
ES29.04.2015
FI29.04.2015
HR29.04.2015
LT29.04.2015
LV29.04.2015
MC29.04.2015
NL29.04.2015
PL29.04.2015
RO29.04.2015
RS29.04.2015
SK29.04.2015
LU18.07.2015
NO29.07.2015
GR30.07.2015
IS29.08.2015
PT31.08.2015
Former [2016/13]AT29.04.2015
CZ29.04.2015
DK29.04.2015
EE29.04.2015
ES29.04.2015
FI29.04.2015
HR29.04.2015
LT29.04.2015
LV29.04.2015
MC29.04.2015
NL29.04.2015
PL29.04.2015
RO29.04.2015
RS29.04.2015
SK29.04.2015
NO29.07.2015
GR30.07.2015
IS29.08.2015
PT31.08.2015
Former [2016/10]AT29.04.2015
CZ29.04.2015
DK29.04.2015
EE29.04.2015
ES29.04.2015
FI29.04.2015
HR29.04.2015
LT29.04.2015
LV29.04.2015
NL29.04.2015
PL29.04.2015
RO29.04.2015
RS29.04.2015
SK29.04.2015
NO29.07.2015
GR30.07.2015
IS29.08.2015
PT31.08.2015
Former [2016/09]AT29.04.2015
DK29.04.2015
EE29.04.2015
ES29.04.2015
FI29.04.2015
HR29.04.2015
LT29.04.2015
LV29.04.2015
NL29.04.2015
RS29.04.2015
NO29.07.2015
GR30.07.2015
IS29.08.2015
PT31.08.2015
Former [2016/07]AT29.04.2015
DK29.04.2015
ES29.04.2015
FI29.04.2015
HR29.04.2015
LT29.04.2015
LV29.04.2015
NL29.04.2015
RS29.04.2015
NO29.07.2015
GR30.07.2015
IS29.08.2015
PT31.08.2015
Former [2015/51]AT29.04.2015
ES29.04.2015
FI29.04.2015
HR29.04.2015
LT29.04.2015
LV29.04.2015
NL29.04.2015
RS29.04.2015
NO29.07.2015
GR30.07.2015
IS29.08.2015
PT31.08.2015
Former [2015/50]ES29.04.2015
FI29.04.2015
HR29.04.2015
LT29.04.2015
LV29.04.2015
NL29.04.2015
RS29.04.2015
NO29.07.2015
GR30.07.2015
IS29.08.2015
PT31.08.2015
Former [2015/49]ES29.04.2015
FI29.04.2015
HR29.04.2015
LT29.04.2015
LV29.04.2015
NL29.04.2015
RS29.04.2015
NO29.07.2015
GR30.07.2015
PT31.08.2015
Former [2015/42]NL29.04.2015
Cited inInternational search[XP]WO2011046970  (MYREXIS INC [US], et al) [XP] 1-4,7-9,12-14,20-26 * example 36; claims 1-15,19-21,23,26-58 *;
 [AD]WO2009032861  (SCRIPPS RESEARCH INST [US], et al) [AD] 1-22,24,25 * examples 19-22,25-29,38-40,129, 130,291,293; claims 1,29-36 *;
 [AD]WO2005012262  (CYCLACEL LTD [GB], et al) [AD] 1,21,22,24,25 * page 76 - page 87; claims 1,35-37,50 *
by applicantWO2005012262
 WO2009032861
 WO2008062044
    - BOEHM ET AL., CELL, (2007), vol. 129, pages 1065 - 1079
    - GUO ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, (2010), vol. 285, pages 3676 - 3684
    - GUO ET AL., THE AMERICAN JOURNAL OF PATHOLOGY, (2009), vol. 175, pages 324 - 333
    - CHIANG ET AL., CELL, (2009), vol. 138, pages 961 - 975
    - BARBIE ET AL., NATURE, (2009), vol. 462, no. 5, pages 108 - 114
    - OU ET AL., MOLECULAR CELL, (2011), vol. 41, pages 458 - 70
    - XIE ET AL., PNAS, (2011), vol. 108, no. 16, pages 6474 - 6479
    - LEE ET AL., J. ORG. CHEM, (1989), pages 428 - 431
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.